

## **Publikationen von Prof. Dr. med. Thomas Müller zur intrathekalen Therapie bei MS-Patienten**

1. Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. Hoffmann V, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N, Pöhlau D, Przuntek H, Müller T. *Journal of Neurological Sciences* 2003; 211(1-2): 81 – 84.
2. Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms. Hellwig K, Stein FJ, Przuntek H and Müller T. *BMC Neurology* 2004; 4:18
3. Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients. Hoffmann V, Kuhn W, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N, Pöhlau D, Przuntek H, and Müller T. *European Journal of Neurology* 2006; 13: 72 – 76.
4. Repeat intrathecal triamcinolone acetonide application reduces acute occurring painful dysesthesia in patients with relapsing remitting multiple sclerosis. Hellwig K, Lukas C, Brune N, Hoffmann V, Schimrigk S, Przuntek H and Müller T. *ScientificWorldJournal* 2006; 6: 460 – 465.
5. Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients. Hellwig K, Lukas C, Schimrigk S, Hoffmann V, Brune N, Przuntek H and Müller T. *Clinical Neuropharmacology* 2006; 29(5): 286 – 289
6. Reduction in the free radical status and clinical benefit of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. Müller T, Herrling T, Lütge S, Kuchler M, Lohse L, Rothe H, Haas T, Marg M, Öhm G, and Jung K. *Clinical Neuropharmacology* 2014 Jan-Feb;37(1):22-5
7. One time intrathecal triamcinolone acetonide application increases reduced proteins in cerebrospinal fluid of progressive multiple sclerosis patients: a pilot study. Müller T, Herrling T, Lütge S, Lohse L, Öhm G and Jung K. *Therapeutic Advances in Neurological Disorders* 2016 Jul;9(4):264-8. doi: 10.1177/1756285616636551
8. Decreased levels of repulsive guidance molecule A in association with beneficial effects of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. Müller T, Barghorn S, Lütge S, Haas T, Mueller R, Gerlach B, Öhm G, Eilert K, Trommer I, Mueller BK. *JJ Neural Transm (Vienna)*. 2015 Jun;122(6):841-8. doi: 10.1007/s00702-014-1308-x
9. Targeting repulsive guidance molecule A to promote regeneration and neuroprotection in multiple sclerosis. Demicheva E, Cui YF, Bardwell P, Barghorn S, Kron M, Meyer AH, Schmidt M, Gerlach B, Leddy M, Barlow E, O'Connor E, Choi CH, Huang L, Veldman GM, Rus H, Shabanzadeh AP, Tassew NG, Monnier PP, Müller T, Calabresi PA, Schoemaker H, Mueller BK. *Cell Rep*. 2015 Mar 24;10(11):1887-98
10. The role of intraspinal steroid application in patients with multiple sclerosis. Müller T. *Expert Review of Neurotherapeutics* 2009; 9(9): 1279 – 1287.